13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
41 檔
29.2%
In Q3 2025, Sector Gamma As's U.S. equity holdings reached a combined market value of $461.0M, distributed across 41 disclosed stock positions.
In Q3 2025, Sector Gamma As displayed an active expansion posture, initiating 12 new positions and adding to 19 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including PFE, MDT, MRK) accounted for 29.2% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer Inc | Stock-Healthcare | 7.91% | -1.99% | +36.10% | |
| 2 | MDT | Medtronic plc | Stock-Healthcare | 7.17% | +0.24% | +35.46% | |
| 3 | MRK | Merck & Co. Inc. | Stock-Healthcare | 6.71% | -1.34% | +59.65% | |
| 4 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 6.50% | -2.78% | +43.17% | |
| 5 | BDX | Becton Dickinson And Co | Stock-Healthcare | 5.05% | -0.01% | +11.05% | |
| 6 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 4.40% | +0.26% | -5.21% | |
| 7 | INCY | Incyte CORP | Stock-Healthcare | 4.31% | -0.26% | +0.55% | |
| 8 | AMGN | Amgen Inc | Stock-Healthcare | 4.30% | -1.86% | +39.67% | |
| 9 | GILD | Gilead Sciences Inc | Stock-Healthcare | 4.05% | -1.75% | EXIT | |
| 10 | CVS | Cvs Health CORP | Stock-Healthcare | 2.92% | +1.19% | -4.17% | |
| 11 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 2.77% | -0.67% | +28.03% | |
| 12 | BIIB | Biogen Inc | Stock-Healthcare | 2.62% | -1.36% | +49.05% | |
| 13 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.36% | +0.46% | +43.73% | |
| 14 | CAH | Cardinal Health Inc | Stock-Healthcare | 2.32% | -0.64% | -9.79% | |
| 15 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.22% | +3.65% | NEW | |
| 16 | BAX | Baxter International Inc | Stock-Healthcare | 2.15% | — | +42.37% | |
| 17 | GEHC | GE Healthcare Technology | Stock-Healthcare | 2.07% | +0.77% | +50.53% | |
| 18 | BRKR | Bruker CORP | Stock-Healthcare | 2.02% | -0.18% | +28.03% | |
| 19 | CNC | Centene CORP | Stock-Healthcare | 1.89% | +1.00% | +40.27% | |
| 20 | LH | Labcorp Holdings Inc | Stock-Healthcare | 1.85% | +0.38% | +33.29% | |
| 21 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.80% | +0.56% | +28.03% | |
| 22 | VTRS | Viatris Inc | Stock-Healthcare | 1.64% | — | — | |
| 23 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.59% | +0.56% | +28.03% | |
| 24 | HUM | Humana Inc | Stock-Healthcare | 1.54% | -0.79% | EXIT | |
| 25 | ELAN | Elanco Animal Health Inc | Stock-Healthcare | 1.53% | — | +5.20% | |
| 26 | AVTR | Avantor Inc | Stock-Healthcare | 1.48% | +0.66% | +28.03% | |
| 27 | OGN | Organon & Co | Stock-Healthcare | 1.44% | +0.27% | — | |
| 28 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.41% | +0.05% | +73.76% | |
| 29 | DXCM | Dexcom Inc | Stock-Healthcare | 1.28% | +0.66% | +53.64% | |
| 30 | ASND | Ascendis Pharma A/S | Stock-Other | 1.20% | -1.15% | EXIT | |
| 31 | HCA | Hca Healthcare Inc | Stock-Healthcare | 1.15% | — | +36.04% | |
| 32 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.08% | — | — | |
| 33 | SOLV | Solventum CORP | Stock-Healthcare | 1.07% | — | +55.94% | |
| 34 | KURA | Kura Oncology Inc | Stock-Other | 0.96% | +0.24% | — | |
| 35 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.82% | -1.67% | EXIT | |
| 36 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 0.81% | -0.34% | +28.03% | |
| 37 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.80% | -0.43% | — | |
| 38 | ELV | Elevance Health Inc | Stock-Healthcare | 0.77% | +0.69% | -48.86% | |
| 39 | CERT | Certara Inc | Stock-Other | 0.70% | — | — | |
| 40 | BNTX | Biontech Se-adr | Stock-Other | 0.68% | — | -25.99% | |
| 41 | ACLXGBX | Arcellx Inc | Stock-Other | 0.65% | — | +28.04% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BIIB | Biogen Inc | +1.8% | +49.05% | Add |
| 2 | IONS | Ionis Pharmaceuticals Inc | +1.6% | -5.21% | Trim |
| 3 | MDT | Medtronic plc | +1.3% | +35.46% | Add |
| 4 | INCY | Incyte CORP | +1.2% | +0.55% | Add |
| 5 | BIO | Bio-rad Laboratories-a | +0.5% | +28.03% | Add |
| 6 | GEHC | GE Healthcare Technology | +0.5% | +50.53% | Add |
| 7 | PFE | Pfizer Inc | +0.4% | +36.10% | Add |
| 8 | ASND | Ascendis Pharma A/S | +0.4% | +43.10% | Add |
| 9 | SOLV | Solventum CORP | +0.3% | +55.94% | Add |
| 10 | PTCT | Ptc Therapeutics Inc | +0.3% | +28.03% | Add |
| 11 | LNTH | Lantheus Holdings Inc | 0% | +28.04% | Add |
| 12 | ELAN | Elanco Animal Health Inc | -0.1% | +5.20% | Trim |
| 13 | ACLXGBX | Arcellx Inc | -0.1% | +28.04% | Trim |
| 14 | BNTX | Biontech Se-adr | -0.2% | -25.99% | Trim |
| 15 | TNDM | Tandem Diabetes Care Inc | -0.3% | +28.03% | Add |
| 16 | BAX | Baxter International Inc | -0.6% | +42.37% | Add |
| 17 | HUM | Humana Inc | -0.6% | +1.88% | Trim |
| 18 | BMRN | Biomarin Pharmaceutical Inc | -0.8% | +43.73% | Add |
| 19 | BRKR | Bruker CORP | -0.8% | +28.03% | Add |
| 20 | BDX | Becton Dickinson And Co | -1% | +11.05% | Add |
| 21 | GILD | Gilead Sciences Inc | -1% | +15.94% | Add |
| 22 | ZBH | Zimmer Biomet Holdings Inc | -1.4% | +28.03% | Trim |
| 23 | EW | Edwards Lifesciences CORP | -1.5% | +73.76% | Trim |
| 24 | CVS | Cvs Health CORP | -1.5% | -4.17% | Trim |
| 25 | CNC | Centene CORP | -1.6% | +40.27% | Add |
| 26 | CAH | Cardinal Health Inc | -1.6% | -9.79% | Trim |
| 27 | AMGN | Amgen Inc | -1.6% | +39.67% | Add |
| 28 | BMY | Bristol-myers Squibb Co | -2% | +43.17% | Add |
| 29 | ELV | Elevance Health Inc | -3.2% | -48.86% | Trim |
| 30 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 31 | JNJ | Johnson & Johnson | — | EXIT | Sold out |
| 32 | TMO | Thermo Fisher Scientific Inc | — | NEW | New buy |
| 33 | QGEN | Qiagen N.V. | — | EXIT | Sold out |
| 34 | LH | Labcorp Holdings Inc | — | NEW | New buy |
| 35 | VTRS | Viatris Inc | — | NEW | New buy |
| 36 | AVTR | Avantor Inc | — | NEW | New buy |
| 37 | OGN | Organon & Co | — | NEW | New buy |
| 38 | THC | Tenet Healthcare CORP | — | EXIT | Sold out |
| 39 | DXCM | Dexcom Inc | — | NEW | New buy |
| 40 | HCA | Hca Healthcare Inc | — | NEW | New buy |
| 41 | ICLR | ICON Public Limited Company | — | NEW | New buy |
| 42 | KURA | Kura Oncology Inc | — | NEW | New buy |
| 43 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 44 | CERT | Certara Inc | — | NEW | New buy |
| 45 | TGTX | Tg Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 41 disclosed positions in Q3 2025.
During Q3 2025, Sector Gamma As's top holdings by market value included PFE (7.9%)、MDT (7.2%)、MRK (6.7%). The largest single position, PFE, represented 7.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
MRK
市值: $27.1M
Top Position Liquidated / Trimmed
JNJ
前期市值: $16.3M
In Q3 2025, Sector Gamma As made 45 total portfolio adjustments, initiating 12 new buys, adding to 19 positions, trimming 10 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.